Open Access

Prognostic role of matrix metalloproteinase 9 in early breast cancer

  • Authors:
    • Katarina Kalavska
    • Zuzana Cierna
    • Marian Karaba
    • Gabriel Minarik
    • Juraj Benca
    • Tatiana Sedlackova
    • Denisa Kolekova
    • Ivana Mrvova
    • Daniel Pindak
    • Jozef Mardiak
    • Michal Mego
  • View Affiliations

  • Published online on: November 30, 2020     https://doi.org/10.3892/ol.2020.12339
  • Article Number: 78
  • Copyright: © Kalavska et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MMP9 is involved in extracellular matrix degradation during various physiological and pathological conditions, including tumorigenesis. The present study aimed to assess the prognostic role of intratumoral MMP9 and to determine its association with circulating tumor cells (CTCs) in patients with early breast cancer. A total of 318 patients with primary breast cancer (PBC) were enrolled into the present study. Specimens were subjected to immunohistochemistry analysis, using the MMP9 monoclonal antibody. MMP9 expression was scored using a weighted histoscore (WH). The results demonstrated that the mean WH ± SEM for MMP9 expression was significantly higher in breast tumor cells compared with tumor associated stromas (132.0±5.2 vs. 50.8±3.7; P<0.00001). Furthermore, a positive association was observed between MMP9 expression, the hormone positive status and proliferation index of analysed breast cancer tumour cells. Notably, the prognostic role of MMP9 was not observed in tumor cells [hazard ratio (HR) =0.96; 95% confidence interval (CI), 0.58‑1.59; P=0.864] or tumor associated stroma (HR=1.29; 95% CI, 0.60‑2.78; P=0.547). Subgroup analysis demonstrated that patients that were HR negative or triple negative, with low MMP9 expression in tumor cells and stroma had a significantly improved disease‑free survival than patients with high MMP9 expression. Taken together, the results of the present study demonstrated that high MMP9 expression in PBC was associated with favorable tumor characteristics. However, the prognostic value of MMP9 was limited to only the HR negative and CTC epithelial‑to‑mesenchymal transition positive subgroups. Thus, analyzing MMP9 tumor expression may help identify patients with increased risk of disease recurrence in these subgroups.
View Figures
View References

Related Articles

Journal Cover

February-2021
Volume 21 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kalavska K, Cierna Z, Karaba M, Minarik G, Benca J, Sedlackova T, Kolekova D, Mrvova I, Pindak D, Mardiak J, Mardiak J, et al: Prognostic role of matrix metalloproteinase 9 in early breast cancer. Oncol Lett 21: 78, 2021
APA
Kalavska, K., Cierna, Z., Karaba, M., Minarik, G., Benca, J., Sedlackova, T. ... Mego, M. (2021). Prognostic role of matrix metalloproteinase 9 in early breast cancer. Oncology Letters, 21, 78. https://doi.org/10.3892/ol.2020.12339
MLA
Kalavska, K., Cierna, Z., Karaba, M., Minarik, G., Benca, J., Sedlackova, T., Kolekova, D., Mrvova, I., Pindak, D., Mardiak, J., Mego, M."Prognostic role of matrix metalloproteinase 9 in early breast cancer". Oncology Letters 21.2 (2021): 78.
Chicago
Kalavska, K., Cierna, Z., Karaba, M., Minarik, G., Benca, J., Sedlackova, T., Kolekova, D., Mrvova, I., Pindak, D., Mardiak, J., Mego, M."Prognostic role of matrix metalloproteinase 9 in early breast cancer". Oncology Letters 21, no. 2 (2021): 78. https://doi.org/10.3892/ol.2020.12339